GT201500267A - Anticuerpos anti-cd52 - Google Patents

Anticuerpos anti-cd52

Info

Publication number
GT201500267A
GT201500267A GT201500267A GT201500267A GT201500267A GT 201500267 A GT201500267 A GT 201500267A GT 201500267 A GT201500267 A GT 201500267A GT 201500267 A GT201500267 A GT 201500267A GT 201500267 A GT201500267 A GT 201500267A
Authority
GT
Guatemala
Prior art keywords
antibodies
fragments
hospeding
rejection
union
Prior art date
Application number
GT201500267A
Other languages
English (en)
Inventor
Qiu Huawei
Rong Wei Ronnie
Qun Pan Clark
Sendak Rebecca
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201500267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of GT201500267A publication Critical patent/GT201500267A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

LA PRESENTE INVENCIÓN DESCRIBE ANTICUERPOS ANTI-CD52 HUMANA Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS. TAMBIÉN SE PROPORCIONAN ÁCIDOS NUCLEICOS AISLADOS, VECTORES RECOMBINANTES Y CÉLULAS HOSPEDANTES PARA PREPARAR LOS ANTICUERPOS Y FRAGMENTOS. LOS ANTICUERPOS Y FRAGMENTOS SE PUEDEN USAR EN APLICACIONES TERAPÉUTICAS PARA TRATAR, POR EJEMPLO, ENFERMEDADES AUTOINMUNES, CÁNCER Y RECHAZO DE INJERTOS.
GT201500267A 2013-03-15 2015-09-09 Anticuerpos anti-cd52 GT201500267A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
GT201500267A true GT201500267A (es) 2017-12-15

Family

ID=50391542

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500267A GT201500267A (es) 2013-03-15 2015-09-09 Anticuerpos anti-cd52

Country Status (36)

Country Link
US (2) US9708407B2 (es)
EP (1) EP2970467B1 (es)
JP (2) JP6482524B2 (es)
KR (1) KR20150131286A (es)
CN (1) CN105209495B (es)
AR (1) AR095199A1 (es)
AU (1) AU2014233685B2 (es)
BR (1) BR112015022464A2 (es)
CA (1) CA2906539A1 (es)
CL (1) CL2015002705A1 (es)
CR (1) CR20150547A (es)
CY (1) CY1121795T1 (es)
DK (1) DK2970467T3 (es)
DO (1) DOP2015000211A (es)
EA (1) EA031730B1 (es)
ES (1) ES2710976T3 (es)
GT (1) GT201500267A (es)
HK (1) HK1219963A1 (es)
HR (1) HRP20190085T1 (es)
HU (1) HUE041796T2 (es)
IL (1) IL241410A0 (es)
LT (1) LT2970467T (es)
MA (1) MA38485A1 (es)
MX (1) MX2015012991A (es)
NZ (1) NZ631473A (es)
PE (1) PE20151757A1 (es)
PH (1) PH12015501932A1 (es)
PL (1) PL2970467T4 (es)
PT (1) PT2970467T (es)
SG (1) SG11201506932SA (es)
SI (1) SI2970467T1 (es)
TN (1) TN2015000415A1 (es)
TR (1) TR201900638T4 (es)
TW (1) TWI644923B (es)
UY (1) UY35440A (es)
WO (1) WO2014151644A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
MX342907B (es) 2009-05-13 2016-10-17 Genzyme Corp * El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
PL3079322T3 (pl) * 2014-01-28 2021-01-11 Huawei Technologies Co., Ltd. Sposób wskazywania transmisji danych, punkt dostępowy i terminal
EP3612564A2 (en) * 2017-04-21 2020-02-26 Genzyme Corporation Treatment of multiple sclerosis with anti-cd52 antibodies
MX2020008446A (es) * 2018-02-13 2020-09-28 Merck Sharp & Dohme Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
US20220288118A1 (en) * 2019-07-31 2022-09-15 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
WO2024038839A1 (ja) * 2022-08-15 2024-02-22 国立大学法人 東京大学 糸状菌を用いた免疫グロブリンまたは多量体免疫グロブリンの製造方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1987006265A1 (en) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US5641780A (en) 1994-04-22 1997-06-24 Kyowa Hakko Kogyo Co., Ltd. Pyrrolo-indole derivatives
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2003057881A1 (fr) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1618891A1 (en) 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
EP1694706B1 (en) 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2006126068A2 (en) 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
CN102441163A (zh) * 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 结合tweak的抗体
JP2009521909A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
ES2547333T3 (es) 2006-04-12 2015-10-05 Genzyme Corporation Métodos para tratar enfermedades autoinmunes
EP2433649A3 (en) 2006-09-13 2012-10-31 Alcafleu Management GmbH & Co. KG Treatment of multiple sclerosis (MS) with campath-1H
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
CA2679400A1 (en) * 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
EP2160408A1 (en) 2007-06-22 2010-03-10 Bayer Schering Pharma Aktiengesellschaft Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
EP2429582A4 (en) * 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
EP2429584A4 (en) 2009-05-13 2013-02-20 Genzyme Corp TREATMENT PROCEDURE AND COMPOSITIONS
MX342907B (es) 2009-05-13 2016-10-17 Genzyme Corp * El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
AR077756A1 (es) * 2009-07-15 2011-09-21 Genentech Inc Anticuerpos especificos para bacterias gram-positivas
EP4219805A1 (en) * 2010-07-16 2023-08-02 Adimab, LLC Antibody libraries

Also Published As

Publication number Publication date
HUE041796T2 (hu) 2019-05-28
CN105209495A (zh) 2015-12-30
TN2015000415A1 (en) 2017-01-03
MX2015012991A (es) 2015-12-15
LT2970467T (lt) 2019-02-11
ES2710976T3 (es) 2019-04-29
MA38485A1 (fr) 2017-06-30
PL2970467T3 (pl) 2019-07-31
US9708407B2 (en) 2017-07-18
PE20151757A1 (es) 2015-12-03
PH12015501932A1 (en) 2016-01-04
TR201900638T4 (tr) 2019-03-21
SI2970467T1 (sl) 2019-03-29
AU2014233685B2 (en) 2019-02-28
EA201591796A1 (ru) 2016-01-29
UY35440A (es) 2014-10-31
AU2014233685A1 (en) 2015-10-01
CR20150547A (es) 2016-01-08
KR20150131286A (ko) 2015-11-24
PT2970467T (pt) 2019-01-28
TW201522373A (zh) 2015-06-16
JP6482524B2 (ja) 2019-03-13
HK1219963A1 (zh) 2017-04-21
CL2015002705A1 (es) 2016-04-22
EA031730B1 (ru) 2019-02-28
CY1121795T1 (el) 2020-07-31
US20170349665A1 (en) 2017-12-07
DK2970467T3 (en) 2019-02-11
AR095199A1 (es) 2015-09-30
CA2906539A1 (en) 2014-09-25
NZ631473A (en) 2017-09-29
PL2970467T4 (pl) 2019-07-31
WO2014151644A3 (en) 2015-01-15
CN105209495B (zh) 2020-06-26
US20160024219A1 (en) 2016-01-28
TWI644923B (zh) 2018-12-21
IL241410A0 (en) 2015-11-30
JP2019069960A (ja) 2019-05-09
EP2970467A2 (en) 2016-01-20
WO2014151644A2 (en) 2014-09-25
DOP2015000211A (es) 2015-11-30
HRP20190085T1 (hr) 2019-03-08
BR112015022464A2 (pt) 2017-10-24
EP2970467B1 (en) 2018-10-17
SG11201506932SA (en) 2015-09-29
JP2016518333A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
GT201500267A (es) Anticuerpos anti-cd52
CL2018001369A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia de cáncer (divisional solicitud 201700836)
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
MX2022008085A (es) Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112018067696A2 (pt) membros de ligação à pd-l1
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
BR112018068678A2 (pt) anticorpos anti-mica
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
BR112017019914A2 (pt) receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
UY35399A (es) Conjugados de fármacos con anticuerpos
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
PH12019500571A1 (en) Anti-pd-1 antibodies
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
EP3494231A4 (en) METHODS FOR IDENTIFYING NEW PROTEINS AND NEW ANTIGENS IN CANCER CELLS
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения
EA201992136A1 (ru) Антитела против pd-l1
EA201890489A1 (ru) Car макрофагов (moto-car) в иммунотерапии